Navigation Links
Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
Date:12/20/2007

/p>

leukemia;

-- AEG41174 is a novel, non-ATP competitive, small molecule tyrosine

kinase inhibitor targeting therapeutically significant kinases

including JAK2 and Bcr-Abl, and is currently in a Phase 1 clinical

trial;

-- AEG33773 is a novel, orally active small molecule developed to treat

painful diabetic neuropathy; definitive IND-enabling preclinical

toxicology testing has been completed.

For more information about Aegera, please visit the website: http://www.aegera.com.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa- 2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancers.

For more information about Human Genome Sciences, please visit the Company's web site at http://www.hgsi.com. Health professionals interested in information about clinical trials involving HGS products are encouraged to inquire via the Contact Us section of the Human Genome Sciences web site, http://www.hg
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... 11 Dendreon Corporation (Nasdaq: DNDN ... previously announced public offering have exercised in full ... of common stock at the public offering price ... the option increases the size of the offering ... stock. Dendreon expects to receive net proceeds ...
(Date:12/11/2009)... DIEGO, Dec. 11 Ambit Biosciences Corporation announced ... Texas M. D. Anderson Cancer Center of the first ... Monotherapy E fficacy) Phase 2 pivotal ... leukemia (AML). AC220 is a novel, orally available, ... designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. ...
(Date:12/11/2009)... 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ... the appointment of Dr. Alan Warrander to the ... Business Development. ,, "Dr. Warrander will be responsible ... for REOLYSIN(R)," said Dr. Brad Thompson, President and ... the design of a Phase 3 trial examining ...
(Date:12/10/2009)... Endologix, Inc. (Nasdaq: ELGX ), ... announced today that Dan Lemaitre, former President and ... of Directors effective December 11, 2009. Endologix ... directors. ,, Franklin D. Brown, Chairman of the ... Lemaitre to the Endologix Board of Directors. ...
Breaking Biology Technology:Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Endologix Appoints Dan Lemaitre to its Board of Directors 2
... treats cancer, patients quickly and effectively ... Mich., Oct. 30 Beaumont Hospital, Royal Oak,(Royal ... using the new,Elekta Axesse(TM), the ultimate whole-body cancer ... and therapeutic efficacy in,stereotactic radiation therapy, which involves ...
... Reduces Bacteria to Levels below Detection; Can ... Permanent Protection in Everyday Products, HAMPTON, N.H., Oct. ... embed a natural balance of silver and copper,into fiber, ... percent effective in killing methicillin-resistant Staphylococcus,aureus (MRSA) bacteria to ...
... Broaden Offerings in the Pharmaceutical Value Chain, ... ShangPharma Corporation,("ShangPharma" or the "Group"), a leading ... company, today announced,that leading global private investment ... TPG Biotech Fund (collectively known as "TPG"), ...
Other Biology Technology:Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse 2Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse 3Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse 4Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA 'Superbug' 2Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA 'Superbug' 3Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA 'Superbug' 4Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA 'Superbug' 5ShangPharma Receives Strategic Investment from TPG 2ShangPharma Receives Strategic Investment from TPG 3ShangPharma Receives Strategic Investment from TPG 4
(Date:12/11/2009)... global "green" trend, educators worldwide are relying ... students, science knowledge. Studies have revealed that ... not just science scoresenvironmental-based lessons can also ... areas. Naturally, educators are interested in developing ... into the classroom in hopes of piquing ...
(Date:12/11/2009)... wild apples that could be an ancestor of today,s ... Asia. A new study comparing the diversity of recently ... Armenia with previously collected varieties originating in Russia and ... collection that will make M. orientalis more ... identify and record the genetic diversity of these wild ...
(Date:12/11/2009)... studying how bacteria under stress collectively weigh and initiate ... into how humans make strategic decisions that affect their ... , Their study, published this week in the early ... National Academy of Sciences , was accomplished when the ... describe the complex interplay of genes and proteins that ...
Breaking Biology News(10 mins):Students learn environmental stewardship, improve science scores 2Understanding apples' ancestors 2Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5TGen and USC researchers find genetic markers to help fight diabetes 49031 1TGen and USC researchers find genetic markers to help fight diabetes 49031 2TGen and USC researchers find genetic markers to help fight diabetes 49031 3Global Med Technologies 28R 29 Licenses Transfusion Software Solution to Nationwide Healthcare System 49027 1Global Med Technologies 28R 29 Licenses Transfusion Software Solution to Nationwide Healthcare System 49027 2Global Med Technologies 28R 29 Licenses Transfusion Software Solution to Nationwide Healthcare System 49027 3Strativas Development Partner BioAlliance Pharma Submits Loramyc 28R 29 NDA 12647 1Strativas Development Partner BioAlliance Pharma Submits Loramyc 28R 29 NDA 12647 2
... Indonesian islands of Borneo and Sumatra, scientists from Duke ... they say is the first demonstration in primates of ... size. , Based on their comparative study, the scientists ... supplies are frequently depleted may have evolved through the ...
... evidence that the dinosaurs and most their contemporaries were ... according to a paleontologist who says multiple meteor impacts, ... the end of the Cretaceous Period. , The ... and earlier of a series of meteors and volcanic ...
... Researchers have achieved an effective immune response to an ... of the norm when they added a chemical mixture ... November 1 issue of Clinical Infectious Diseases, now available ... that increases the immune system's ability to respond to ...
Other Biology News:Study suggests evolutionary link between diet, brain size in orangutans 2Study suggests evolutionary link between diet, brain size in orangutans 3Study suggests evolutionary link between diet, brain size in orangutans 4'Fruit fly dating game' provides clues to our reproductive prowess 2'Fruit fly dating game' provides clues to our reproductive prowess 3
Request Info...
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
Myeloid Marker (BM-1)...
Form: Concentrated Applications: ELISA...
Biology Products: